IVIM Health vs LillyDirect (Zepbound) (2026): prices, structure, verdict

On tirzepatide, IVIM Health↗ is cheaper: $278 versus $449 a month all-in — a $171 monthly gap, $2,052 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, only IVIM Health has a rankable figure: $149 a month all-in; LillyDirect (Zepbound)↗ does not offer semaglutide.

§ Side by side

§ Each record, read aloud

The two records, condensed

IVIM Health: the record, condensed

On tirzepatide, the number that matters at IVIM Health is $278 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The structure is tiered: the advertised entry point is $208, but the maintenance figure — the one a full year is actually billed at — is $278. That $70 gap between the ad and the anniversary is the single most important line in this record.

Inside that $278 sits a mandatory $75-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $203, and it is not a price anyone can actually pay, because the membership cannot be declined.

Context for that figure: it ranks #3 of 17 in the verified tirzepatide index — $63/month above the floor (NexLife↗, $215) — and sits $171 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,336.

On semaglutide, the number that matters at IVIM Health is $149 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. The figure is quoted at maintenance without a separate teaser tier, which keeps the arithmetic honest by default.

A required $75/month membership is part of the deal, and part of the figure above: $74 of medication plus $75 of platform equals the $149 that leaves your account. Judge the membership by what it includes, but compare on the total.

To place the number: #3 of 20 verified programs, with the floor $16/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $200 a month. A year at this figure: $1,788 monthly-billed.

Operationally at IVIM Health: shipping included; commitment membership mandatory for duration; cancellation membership mandatory; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the IVIM Health page · visit IVIM Health ↗

LillyDirect (Zepbound): the record, condensed

LillyDirect (Zepbound)’s tirzepatide program bills $449 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Note the shape: $299 is the number in the marketing, $449 is the number at maintenance. The $150 difference is not a fee or a trick per se — it is dose-tiered pricing doing what dose-tiered pricing does — but it means the advertised figure describes month one, not month twelve.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #0 of 17 in the verified tirzepatide index — $234/month above the floor (NexLife, $215) — and sits $0 over the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $5,388.

Operationally at LillyDirect (Zepbound): shipping included (or same-day retail pickup); commitment 45-day refill cadence to keep pricing; cancellation no subscription; refill-window rules apply; pharmacy named (Eli Lilly direct / retail partners); states: 50 states; evidence source-verified, captured 2026-08-09. The full record with source and archive links: the LillyDirect (Zepbound) page · visit LillyDirect (Zepbound) ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $278 (IVIM Health) against $449 (LillyDirect (Zepbound)). $171 a month sounds survivable; $2,052 a year is a decision.

IVIM Health’s total includes a mandatory $75/month membership; LillyDirect (Zepbound) has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Translate the $171/month spread into medication: $2,052 a year equals roughly 7.4 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: IVIM Health $278/mo month-to-month versus LillyDirect (Zepbound) $449/mo month-to-month. Same winner on both bases — IVIM Health leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: IVIM Health $834 monthly; LillyDirect (Zepbound) $1,347 monthly — best path favors IVIM Health by $513. 6 months: IVIM Health $1,668 monthly; LillyDirect (Zepbound) $2,694 monthly — best path favors IVIM Health by $1,026. 12 months: IVIM Health $3,336 monthly; LillyDirect (Zepbound) $5,388 monthly — best path favors IVIM Health by $2,052. 24 months: IVIM Health $6,672 monthly; LillyDirect (Zepbound) $10,776 monthly — best path favors IVIM Health by $4,104.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

§ Structure vs structure

Everything besides the price

Coverage: IVIM Health publishes “not published”; LillyDirect (Zepbound) publishes “50 states” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: LillyDirect (Zepbound) names its network (Eli Lilly direct / retail partners); IVIM Health does not, which shifts the burden of verification onto your intake questions.

Exit terms: IVIM Health — membership mandatory for duration; membership mandatory. LillyDirect (Zepbound) — 45-day refill cadence to keep pricing; no subscription; refill-window rules apply.

Evidence: IVIM Health source-verified (captured 2026-08-05); LillyDirect (Zepbound) source-verified (2026-08-09).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

§ If you move

Switching between IVIM Health and LillyDirect (Zepbound)

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (IVIM Health: membership mandatory; LillyDirect (Zepbound): no subscription; refill-window rules apply) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings